Whitener Capital Management Inc. raised its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 41.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,982 shares of the medical research company’s stock after buying an additional 2,610 shares during the period. Amgen comprises 0.9% of Whitener Capital Management Inc.’s investment portfolio, making the stock its 24th largest position. Whitener Capital Management Inc.’s holdings in Amgen were worth $1,655,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the business. Geode Capital Management LLC boosted its stake in Amgen by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock valued at $1,720,250,000 after purchasing an additional 482,760 shares during the last quarter. Edge Capital Group LLC purchased a new stake in Amgen during the 4th quarter valued at $546,000. Sontag Advisory LLC purchased a new stake in Amgen during the 4th quarter valued at $91,000. Diag Capital Management LP purchased a new stake in Amgen during the 4th quarter valued at $3,915,000. Finally, Capstone Financial Advisors Inc. boosted its stake in Amgen by 11.5% during the 4th quarter. Capstone Financial Advisors Inc. now owns 1,471 shares of the medical research company’s stock valued at $286,000 after purchasing an additional 152 shares during the last quarter. 78.96% of the stock is currently owned by hedge funds and other institutional investors.
AMGN has been the topic of several recent analyst reports. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Amgen in a research note on Friday, August 9th. Royal Bank of Canada reiterated a “hold” rating on shares of Amgen in a research note on Sunday, August 11th. BidaskClub upgraded Amgen from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Piper Jaffray Companies set a $210.00 target price on Amgen and gave the company a “buy” rating in a research note on Saturday, August 10th. Finally, BMO Capital Markets set a $230.00 target price on Amgen and gave the company a “buy” rating in a research note on Wednesday, July 31st. Nine investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $212.72.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.58 by $0.39. The firm had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The company’s revenue for the quarter was down 3.1% on a year-over-year basis. During the same period last year, the business posted $3.83 EPS. On average, equities research analysts anticipate that Amgen, Inc. will post 14.25 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 6th. Stockholders of record on Thursday, August 15th will be paid a $1.45 dividend. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.84%. Amgen’s dividend payout ratio (DPR) is currently 40.28%.
In related news, Director R Sanders Williams sold 425 shares of Amgen stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total transaction of $77,792.00. Following the transaction, the director now directly owns 16,336 shares in the company, valued at $2,990,141.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $187.58, for a total value of $375,160.00. Following the transaction, the director now owns 16,336 shares in the company, valued at $3,064,306.88. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,425 shares of company stock worth $804,312. Company insiders own 0.25% of the company’s stock.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Recommended Story: Holder of Record
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.